Names & Terms You Will Hear
Plain-language meanings for the terms your care team may use.
| Term | Meaning |
|---|---|
| GLP-1 receptor agonist | A medicine that copies a natural gut hormone called GLP-1. It curbs hunger, slows the stomach, and lowers blood sugar. The whole drug class is named for this hormone. |
| Semaglutide | The most-used GLP-1 drug. Sold as Ozempic and Rybelsus for diabetes, and as Wegovy for weight loss and heart protection. Wegovy is a weekly shot; Rybelsus is a daily pill. |
| Tirzepatide | A newer shot that copies two gut hormones at once — GLP-1 and GIP. Sold as Mounjaro for diabetes and Zepbound for weight loss. It often leads to a bit more weight loss than semaglutide. |
| Incretin | The family of gut hormones (GLP-1 and GIP) that these drugs copy. Incretins are released when you eat and help control hunger and blood sugar. |
| GIP | A second gut hormone. Tirzepatide copies both GIP and GLP-1, which is why it is called a dual agonist. |
| MACE | Short for major adverse cardiovascular events — heart attack, stroke, and death from heart causes. This is what heart trials like SELECT measure. |
| Titration | Starting a drug at a low dose and raising it slowly over weeks. GLP-1 drugs are titrated slowly to limit nausea. |
The big shift: a weight drug that protects the heart.
GLP-1 drugs began as diabetes treatments. The 2023 SELECT trial changed how heart doctors see them — semaglutide cut heart attacks, strokes, and heart deaths by about 20% in people with obesity and heart disease, even without diabetes. These are now part of heart care, not just weight care.
GLP-1 drugs began as diabetes treatments. The 2023 SELECT trial changed how heart doctors see them — semaglutide cut heart attacks, strokes, and heart deaths by about 20% in people with obesity and heart disease, even without diabetes. These are now part of heart care, not just weight care.
What Is GLP-1 Weight-Loss Drugs?
- GLP-1 drugs copy a hormone your gut makes after you eat. That hormone tells your brain you are full, slows how fast your stomach empties, and helps your body handle blood sugar.
- The result is simple: you feel full sooner, eat less, and lose weight. Blood sugar also comes down, which is why these drugs started as diabetes treatments.
- Semaglutide (Ozempic and Wegovy as shots, Rybelsus as a pill) is the most widely used. Tirzepatide (Mounjaro and Zepbound) copies two gut hormones at once and often leads to a bit more weight loss.
- Most are weekly shots you give yourself under the skin with a small, pre-filled pen. The needle is tiny. Rybelsus is a daily tablet.
- These are not stimulants or old-style diet pills. They work with your body's own hunger signals, so the weight loss is steady, not jittery.
- The dose is raised slowly over weeks. This is on purpose — going slow limits the nausea that can come early on.
Why It Matters
- The big change for heart doctors: in the SELECT trial (2023), about 17,600 adults with overweight or obesity and heart disease but NO diabetes took semaglutide. It cut heart attacks, strokes, and heart deaths by about 20%.
- That means these are now heart-protecting drugs — not just weight drugs. The heart benefit does not depend on having diabetes.
- In people with type 2 diabetes, the heart benefit was already proven: semaglutide cut heart events about 26% (SUSTAIN-6) and liraglutide cut them 13% (LEADER).
- The weight loss is large for a medicine. Semaglutide takes off about 15% of body weight on average; tirzepatide takes off up to about 20%. Older diet pills rarely passed 5 to 8%.
- Losing this much weight also lowers blood pressure, improves cholesterol and blood sugar, eases sleep apnea, and reduces strain on the heart.
- New benefit is emerging in heart failure. In STEP-HFpEF, semaglutide improved breathing, walking distance, and quality of life in people with obesity and stiff-heart failure (HFpEF).
How They Work — and Why a Cardiologist Now Cares
- GLP-1 is a hormone your gut releases when you eat. It tells the brain you are full, slows the stomach so food stays longer, and helps the pancreas steady blood sugar.
- These drugs copy that hormone. The natural result is eating less, feeling full sooner, and losing weight — plus lower blood sugar.
- For years they were diabetes drugs. Then SELECT (2023) tested semaglutide in about 17,600 adults with obesity and heart disease but no diabetes.
- Result: about 20% fewer heart attacks, strokes, and heart deaths over roughly 3 years (from 8.0% down to 6.5%). The benefit did not need diabetes to appear.
- Part of the help is weight loss, but the drugs also seem to calm inflammation and ease strain on blood vessels directly.
- That is why a heart doctor now prescribes them: they are becoming heart-protective therapy, not just weight therapy. See our companion guides: Obesity & Heart Health and Diabetes & the Heart.
Risk Factors
Knowing your personal risks helps your care team take extra precautions.
| Risk Factor | Why It Increases Risk |
|---|---|
| Overweight or obesity | These drugs are approved for a BMI of 30 or higher, or 27 or higher with a weight-related problem like high blood pressure, diabetes, or sleep apnea. |
| Established heart disease with extra weight | If you have had a heart attack, stroke, or have known artery disease plus overweight or obesity, semaglutide is now approved to lower your risk of another heart event. |
| Type 2 diabetes | These drugs lower blood sugar and protect the heart and kidneys in diabetes. Many people with diabetes and heart disease are good candidates. |
| Thyroid cancer history (a reason NOT to use) | A personal or family history of medullary thyroid cancer, or the MEN 2 syndrome, means you should not take these drugs. |
Treatment Options
Shown in English for your safety — this section is not automatically translated. Confirm with your doctor or call the office.
- Semaglutide for weight and heart protection (Wegovy): a weekly shot, raised step by step over about 4 to 5 months to the full dose. The slow climb limits nausea.
- Tirzepatide for weight loss (Zepbound): a weekly shot, also titrated up slowly. It often leads to a bit more weight loss than semaglutide.
- For diabetes: Ozempic (semaglutide) or Mounjaro (tirzepatide) are weekly shots; Rybelsus (semaglutide) is a daily pill. These lower blood sugar and protect the heart.
- These work best with healthy eating and regular activity. The drug curbs appetite; your habits decide how well it works and how you feel.
- Keep your protein up and stay active. Some of the weight lost can be muscle. Protein at each meal and strength or resistance activity help protect muscle.
- Plan for the long term. Obesity is a chronic disease. If you stop the drug, appetite and weight tend to come back — like stopping a blood pressure pill.
- Cost and coverage vary. Without insurance these can run high. We help with prior-authorization paperwork and look for the best covered option for you.
The GLP-1 drugs at a glance
| Drug | Brand name(s) | Main use | Note |
|---|---|---|---|
| Semaglutide | Ozempic, Rybelsus | Type 2 diabetes | Weekly shot (Ozempic) or daily pill (Rybelsus). Lowers blood sugar; protects the heart. |
| Semaglutide | Wegovy | Weight loss; lower heart risk | Weekly shot. About 15% weight loss. SELECT: about 20% fewer heart events. |
| Tirzepatide | Mounjaro | Type 2 diabetes | Weekly shot. Copies two gut hormones (GLP-1 and GIP). Strong blood-sugar control. |
| Tirzepatide | Zepbound | Weight loss | Weekly shot. Up to about 20% weight loss — often a bit more than semaglutide. |
Go slow to feel well.
The dose is raised step by step over weeks for a reason — a slow climb is the single best way to limit nausea. Smaller, lower-fat meals, eating slowly, and stopping when full make a big difference. If nausea is rough, call us before stopping; we can adjust the pace.
The dose is raised step by step over weeks for a reason — a slow climb is the single best way to limit nausea. Smaller, lower-fat meals, eating slowly, and stopping when full make a big difference. If nausea is rough, call us before stopping; we can adjust the pace.
Comfort Measures at Home (No Medication Needed)
These simple steps support healing and ease symptoms. Use them alongside any medication your doctor prescribes.
- Eat slowly and stop when full. The drug makes you full faster — rushing a big meal is the most common cause of nausea.
- Keep meals smaller and lower in fat and grease. Heavy, greasy food sits longer in a slowed stomach and brings on queasiness.
- Sip fluids through the day to avoid constipation and stay hydrated, especially in the first weeks.
- Get protein at every meal and add gentle strength activity (bands, light weights, bodyweight moves) to protect muscle as you lose weight.
- Rotate the shot site (belly, thigh, upper arm) each week to keep the skin healthy and limit soreness.
- Take it on the same day each week. Pick a steady routine so you do not miss or double a dose.
Risks, Benefits, and Alternatives
Shown in English for your safety — this section is not automatically translated. Confirm with your doctor or call the office.
Every choice has trade-offs. Use this table to start the shared decision conversation with your care team.
| Option | Risks | Benefits | Alternatives |
|---|---|---|---|
| Semaglutide (Wegovy / Ozempic / Rybelsus) | Nausea, vomiting, constipation (most common, ease with slow dosing). Rare pancreas inflammation or gallbladder problems. Possible muscle loss. Do not use with medullary thyroid cancer or MEN 2. | About 15% average weight loss. About 20% fewer heart attacks, strokes, and heart deaths in obesity with heart disease (SELECT). Proven heart benefit in diabetes (SUSTAIN-6). Better HFpEF symptoms. | Tirzepatide (often a bit more weight loss). SGLT2 inhibitors (for diabetes and heart failure). Lifestyle change. Bariatric surgery. Older weight pills. |
| Tirzepatide (Zepbound / Mounjaro) | Same GI side effects as semaglutide — nausea, vomiting, constipation. Rare pancreas or gallbladder problems. Possible muscle loss. Same thyroid-cancer warning. | Up to about 20% average weight loss — often a bit more than semaglutide. Lowers blood sugar strongly. Heart-outcome trials are ongoing and look promising. | Semaglutide (more heart-outcome data today). Lifestyle change. SGLT2 inhibitors. Bariatric surgery. |
| Lifestyle change alone (eating + activity) | Slow progress; weight is often hard to keep off without added help. No drug side effects, but heart-event reduction is smaller on its own in people with obesity. | Lowers blood pressure, cholesterol, and blood sugar. No drug cost. Always the foundation, with or without medicine. | Add a GLP-1 drug or another weight medicine. Bariatric surgery for severe obesity. |
| No treatment for the extra weight | Ongoing heart strain, higher risk of heart attack, stroke, heart failure, and diabetes. Sleep apnea and joint problems often worsen. | No drug cost or side effects. | Lifestyle change, a GLP-1 drug, an SGLT2 inhibitor, or bariatric surgery — alone or combined. |
Common Misconceptions
| Myth | Reality |
|---|---|
| GLP-1 drugs are just for diabetes — they have nothing to do with my heart. | Not anymore. The SELECT trial showed semaglutide cut heart attacks, strokes, and heart deaths by about 20% in people with obesity and heart disease who did NOT have diabetes. The heart benefit stands on its own. |
| These are just vanity weight-loss drugs. | Obesity is a chronic disease that strains the heart. Losing weight this way lowers blood pressure, blood sugar, and inflammation — and, with semaglutide, directly lowers heart-event risk. This is heart care, not cosmetics. |
| If I lose the weight, I can stop the shot and be done. | Obesity is chronic, like high blood pressure. When the drug stops, appetite returns and most people regain much of the weight. Plan for long-term use, not a quick course. |
| The drug does the work, so I do not need to change how I eat. | The drug curbs appetite, but your habits decide your results — and how you feel. Healthy eating, protein, and activity protect muscle and make side effects milder. It is a tool, not a substitute. |
| Nausea means the drug is hurting me and I should quit. | Mild nausea is common early and usually fades. It is why the dose is raised slowly. Smaller, lower-fat meals and eating slowly help a lot. Call us before stopping — we can adjust the plan. |
| I can keep taking it right up to my surgery. | Tell your surgeon and anesthesia team you take a GLP-1 drug. Because it slows the stomach, food can stay behind and raise the risk during anesthesia. Your team may have you hold it before a procedure. |
Possible Complications
Knowing what can go wrong helps you spot problems early. Most complications are uncommon, especially with treatment.
| Where / What | What Can Happen |
|---|---|
| Stomach and bowel (most common) | Nausea, vomiting, diarrhea, or constipation — usually early and usually mild. Raising the dose slowly, smaller meals, and lower-fat food all help. These ease for most people after the first weeks. |
| Pancreas inflammation (pancreatitis, rare) | Severe, steady belly pain that may spread to the back, often with vomiting. It is uncommon but serious. Stop the drug and seek care if this happens. |
| Gallbladder problems | Fast weight loss can trigger gallstones. Signs are pain in the upper right belly, especially after fatty meals, sometimes with nausea or fever. Let us know if this occurs. |
| Muscle-mass loss | Some of the weight lost can be muscle, not just fat. Protein at each meal plus strength activity helps protect muscle and keeps you strong as you lose weight. |
| Low blood sugar (with certain other drugs) | On its own this class rarely causes lows. But combined with insulin or a sulfonylurea, blood sugar can drop too far. Those doses may need to be lowered. |
| Thyroid C-cell tumors (warning, not for everyone) | In animal studies these drugs caused thyroid tumors. People with a personal or family history of medullary thyroid cancer or MEN 2 should not use them. |
Who They Help — and the Side Effects to Watch
- They are for adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) plus a weight-related problem like high blood pressure, diabetes, or sleep apnea — and for many people with type 2 diabetes.
- They are not for everyone. Cost and insurance coverage can be a barrier. We help with prior-authorization paperwork and finding a covered option.
- The most common side effects are stomach-related: nausea, vomiting, and constipation. The dose is raised slowly on purpose to limit this.
- Less common but important: pancreas inflammation and gallbladder problems. Severe belly pain with vomiting needs prompt care.
- Some weight lost can be muscle. Keep protein up and stay active to protect muscle as you slim down.
- Do NOT use if you or a close family member has medullary thyroid cancer or the MEN 2 syndrome.
Using Them Well — Long-Term, With Lifestyle, and the Surgery Caution
- Think long-term. Obesity is chronic. If you stop the drug, appetite and weight tend to come back — like stopping a blood pressure pill. Plan to stay on it as long as it helps.
- It works with lifestyle, not instead of it. Healthy eating, protein, and activity make the drug work better and the side effects milder. It is a tool, not a shortcut.
- Before any surgery or procedure with anesthesia, tell your team you take a GLP-1 drug. Because it slows the stomach, food can stay behind and raise the risk under anesthesia — your team may hold it beforehand.
- Skip it if you have the thyroid-cancer history above. Always review your full list of conditions and medicines with us first.
- Pair it with the rest of your heart care. For diabetes or heart failure, an SGLT2 inhibitor may be added — see our SGLT2 Inhibitors guide.
- Steady habits matter: same shot day each week, balanced plates, and check-ins so we can adjust the plan. See Heart-Healthy Eating.
Points to Know
Shown in English for your safety — this section is not automatically translated. Confirm with your doctor or call the office.
If you remember nothing else, remember these key points.
- These drugs copy a gut hormone that curbs hunger and slows the stomach, so you eat less and lose weight.
- The big heart news: semaglutide cut heart attacks, strokes, and heart deaths by about 20% in obesity with heart disease — even without diabetes (SELECT).
- Weight loss is large for a medicine — about 15% with semaglutide, up to about 20% with tirzepatide.
- The dose is raised slowly over weeks. This limits nausea. Smaller, lower-fat meals help too.
- Keep protein up and stay active to protect muscle while you lose weight.
- Plan for the long term. If you stop, appetite and weight usually come back. It is a tool used with healthy habits, not a shortcut.
- Tell any surgeon or anesthesia team that you take a GLP-1 drug — it slows the stomach and may need to be held before a procedure.
- Do not use if you or your family have medullary thyroid cancer or MEN 2.
When to Call Us — and When to Call 911
Shown in English for your safety — this section is not automatically translated. Confirm with your doctor or call the office.
If you are not sure, call. We would rather hear from you twice than miss a real problem.
- Severe, steady belly pain (especially spreading to the back) with vomiting — call us or seek care. This can be pancreas inflammation.
- Pain in the upper right belly after fatty meals, with nausea or fever — call us. This can be a gallbladder problem.
- Vomiting or diarrhea you cannot keep up with, or signs of dehydration (dizziness, very little urine) — call us.
- A lump in the neck, trouble swallowing, or a hoarse voice that does not go away — call us promptly.
- Shakiness, sweating, or confusion if you also take insulin or a sulfonylurea — treat the low and call us to adjust doses.
- Before any surgery, scope, or procedure with anesthesia — call us and tell the team you take this drug, so it can be held if needed.
- Nausea bad enough that you cannot eat or drink — call before stopping the drug on your own; we can adjust the plan.
Office: (727) 943-5200
See also: our companion guides.
Obesity & Heart Health · Diabetes & the Heart · SGLT2 Inhibitors · HFpEF · Heart-Healthy Eating.
Obesity & Heart Health · Diabetes & the Heart · SGLT2 Inhibitors · HFpEF · Heart-Healthy Eating.
Trusted Resources
Independent, evidence-based pages we recommend for deeper reading.
- Cleveland Clinic — GLP-1 Agonists — Plain-language overview of how these drugs work, dosing, and side effects.
- Mayo Clinic — Semaglutide for Weight Loss — Patient FAQ on expected weight loss, nausea, and who should consider these drugs.
- NIH NIDDK — Medications to Treat Overweight and Obesity — Federal overview of FDA-approved weight-loss drugs, including GLP-1 and dual agonists.
- American Heart Association — Healthy Weight — AHA guidance on weight and heart health to pair with any medicine.
Sources Used to Build This Guide
- SELECT Trial — Semaglutide and Cardiovascular Outcomes (NEJM 2023) [trial] — Landmark CV outcomes trial: in 17,604 adults with overweight or obesity and established heart disease but NO diabetes, semaglutide 2.4 mg cut major cardiovascular events about 20 percent (6.5 percent vs 8.0 percent, HR 0.80). The core evidence that GLP-1 weight-loss therapy protects the heart.
- STEP 1 — Semaglutide 2.4 mg Once Weekly for Weight Management (NEJM 2021) [trial] — Pivotal weight-loss trial: semaglutide produced about 15 percent average body-weight loss in adults with overweight or obesity without diabetes. Source for the headline weight-loss number.
- SURMOUNT-1 — Tirzepatide Once Weekly for Obesity (NEJM 2022) [trial] — Pivotal tirzepatide (dual GIP/GLP-1) weight trial: 16 percent to about 22.5 percent average weight loss by dose in adults with obesity or overweight. Source for the tirzepatide weight-loss range and dual-agonist framing.
- STEP-HFpEF — Semaglutide in Obesity-Related HFpEF (NEJM 2023) [trial] — In 529 adults with obesity and heart failure with preserved ejection fraction (no diabetes), semaglutide improved symptoms, physical limitation, and 6-minute walk distance more than placebo. Source for the emerging HFpEF benefit.
- SUSTAIN-6 — Semaglutide and CV Outcomes in Type 2 Diabetes (NEJM 2016) [trial] — In 3,297 adults with type 2 diabetes at high CV risk, injectable semaglutide cut major cardiovascular events about 26 percent (HR 0.74). Establishes heart benefit of semaglutide in diabetes.
- LEADER — Liraglutide and CV Outcomes in Type 2 Diabetes (NEJM 2016) [trial] — In 9,340 adults with type 2 diabetes, liraglutide cut major cardiovascular events 13 percent (HR 0.87) and lowered cardiovascular death. One of the first GLP-1 trials to prove heart benefit.
- FDA Label — Wegovy (semaglutide) injection [drug_label] — Official prescribing information: approved indications (including reducing CV risk in established heart disease with obesity), dosing, the slow dose titration schedule, and the medullary thyroid cancer / MEN 2 boxed warning.
- FDA Label — Zepbound (tirzepatide) injection [drug_label] — Official prescribing information for tirzepatide: indications for obesity and obstructive sleep apnea with obesity, dose titration, GI side effects, and the thyroid C-cell tumor warning.
- AHA — Obesity and Cardiovascular Disease Scientific Statement (Circulation 2021) [guideline] — AHA statement linking obesity to heart failure, AFib, coronary disease, and hypertension; frames why weight loss is a cardiovascular intervention, not just cosmetic.
- ASA Guidance — GLP-1 Drugs and Anesthesia / Stopping Before Surgery (2023) [guideline] — American Society of Anesthesiologists guidance on holding GLP-1 drugs before surgery because delayed stomach emptying raises the risk of aspiration under anesthesia. Source for the stop-before-surgery caution.
- Cleveland Clinic — GLP-1 Agonists [patient_page] — Plain-language overview of how GLP-1 drugs work, how they are taken, common side effects, and benefits.
- Mayo Clinic — Semaglutide (Wegovy/Ozempic) for Weight Loss [patient_page] — Patient-facing FAQ on dosing, expected weight loss, nausea management, and who should consider these drugs.
- NIH NIDDK — Prescription Medications to Treat Overweight & Obesity [patient_page] — Federal resource summarizing FDA-approved weight-loss drugs including GLP-1 receptor agonists and dual agonists.
